Company: MDCXW
Filing Date: 2025-05-30
Form Type: 424B3
Source: 0001062993-25-010580
Chunk: 16

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-30
Form: 424B3
Chunk 16
---
 shares authorized; 13,417,561 and 11,816,721 shares issued and outstanding at March 31,2025 and December 31, 2024, respectively |   |     32,908,702 |   |   |        30,518,195 |   |
| Additional paid-in capital                                                                                                                                             |   |      3,245,163 |   |   |         1,520,412 |   |
| Accumulated deficit                                                                                                                                                    |   |    (34,006,311 | ) |   |       (28,903,903 | ) |
| Total shareholders' equity                                                                                                                                             |   |      2,147,554 |   |   |         3,134,704 |   |
| Total liabilities and shareholders' equity                                                                                                                             | $ |      5,657,866 |   | $ |         5,646,878 |   |

<div align='center'>- 8 -

RISK FACTORS</div>

You should carefully consider the risks described below and all other information contained in this prospectus before making an investment decision. If any of the following risks actually occur, our business, financial condition and results of operations could be materially and adversely affected. In that event, the trading price of our securities could decline, and you may lose part or all of your investment. This prospectus also contains forward-looking information that involves risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors, including the risks described below and elsewhere in this prospectus.

We have a limited operating history, which may make it difficult to evaluation our current business and predict our future performance.

We have a limited operating history and, in particular, no history of earnings; we have not paid any dividends and we are unlikely to pay any dividends in the immediate or foreseeable future. Our success will depend to a large extent on the expertise, ability, judgement, discretion, integrity and good faith of our management.

As we are at an early stage of product development, we have not generated revenues to date. We expect to spend a significant amount of capital to fund research and development and clinical trials. As a result, we expect that our operating expenses will increase significantly and, consequently, we will need to generate significant revenues to become profitable. We cannot predict when, if ever, we will be profitable. Even if we do become profitable, we may not be able to sustain or increase profitability on a quarterly or annual